aTyr Pharma, Inc.
ATYR
$0.53
-$0.03-5.75%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.43% | -15.77% | -17.72% | -15.10% | -17.58% |
| Total Depreciation and Amortization | 35.65% | 0.84% | -40.55% | -54.68% | -58.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 251.25% | 1,008.51% | 1,648.77% | 400.49% | 217.86% |
| Change in Net Operating Assets | 748.84% | 207.73% | 270.01% | 207.09% | 69.77% |
| Cash from Operations | 4.95% | 10.32% | 6.16% | 12.37% | -12.99% |
| Capital Expenditure | -347.92% | -18.46% | -24.56% | 91.82% | 98.39% |
| Sale of Property, Plant, and Equipment | 71.43% | 71.43% | -- | -- | -53.33% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -22.14% | -128.85% | -166.80% | -61.72% | -27.72% |
| Cash from Investing | -23.35% | -129.32% | -167.05% | -61.04% | -15.10% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -8.48% | -8.45% | -9.09% | -10.71% | -12.92% |
| Issuance of Common Stock | -6.78% | 64.89% | 210.46% | 84.00% | 105.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -6.94% | 65.59% | 214.06% | 85.15% | 107.50% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -135.39% | 91.45% | -581.85% | 272.39% | 120.00% |